I am sure you are aware that PRR is now IMM and on a downward...

I am sure you are aware that PRR is now IMM and on a downward trajectory.
There are some similarities:
The change of name and a listing on NASDAQ could not stop the steady decline of 34.4%/year.
To compare, TIS changed to FTT with no NASDAQ but a Frankfurt/Germany listing, and the decline is 33.85%/year.
IMM has 2.4 billion shares, FTT only 730 million - here is some potential for a CR.

Long time ago I was a holder of PRR and dropped out because having two Australian biotech upstarts is one too many.
Now it seems that having one Australian biotech upstart is one too many too.